Amaador Karima, Kersten Marie J, Minnema Monique C, Vos Josephine M I
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.
Leuk Lymphoma. 2023 Jan;64(1):30-41. doi: 10.1080/10428194.2022.2131423. Epub 2022 Oct 25.
Waldenström's Macroglobulinemia (WM) is a rare type of indolent non-Hodgkin lymphoma (NHL) that remains incurable. Several effective agents such as monoclonal antibodies (in combination with chemotherapy), Bruton's tyrosine kinase inhibitors, proteasome inhibitors, and BCL2 inhibitors are (becoming) available for the treatment of relapsed and refractory WM. There is however no consensus on a preferred treatment in the relapsed setting. Choice of therapy in relapsed WM should be individualized by taking several treatment and patients characteristics into account, such as treatment duration, toxicity, age, comorbidities and and mutational status. Due to better understanding of WM biology and the arrival of novel anti-lymphoma agents, the therapeutic options are increasing. Non-cytotoxic and fixed duration regimens, such as those explored in other indolent NHLs should be the focus of future clinical trials in WM.
华氏巨球蛋白血症（WM）是一种罕见的惰性非霍奇金淋巴瘤（NHL），目前仍无法治愈。几种有效的药物，如单克隆抗体（与化疗联合使用）、布鲁顿酪氨酸激酶抑制剂、蛋白酶体抑制剂和BCL2抑制剂，可用于治疗复发难治性WM。然而，对于复发情况下的首选治疗方法尚无共识。复发WM的治疗选择应根据多种治疗和患者特征进行个体化考虑，如治疗持续时间、毒性、年龄、合并症以及突变状态。由于对WM生物学的更好理解和新型抗淋巴瘤药物的出现，治疗选择正在增加。非细胞毒性和固定疗程的方案，如在其他惰性NHL中探索的方案，应成为未来WM临床试验的重点。
